Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets.

"data availability the data that support the findings of this study are available at 10 6084/m9 figshare 25006826 or contact the corresponding authors with a written request. data availability the data that support the findings of this study are available at 10 6084/m9 figshare"

"Competing interests S.J.T. is the lead inventor on the ZPIV patent filed by the US Army and assigned all rights to the US Government. K.M. has received funding from the U.S. Defense Health Agency and the National Institutes of Health during the execution of the research described in this manuscript. K.M. is currently an employee of Pfizer, Inc. M.A.B., I.-J.K., J.L.P., C.N.R., and other authors have no competing interests."

"We gratefully acknowledge Dr. Kathleen Engelman at the University Massachusetts for providing the chimeric marmoset anti-ZIKV IgG clone, ZIKV-MAR and Dr. Julienne Rutherford for the examination of the placenta. We express our gratitude to the veterinary technical and marmoset care staff at SNPRC including Jessica Greig, Clarissa Hinojosa, Ernesto Morin, and Ariana Alvarez for their assistance with the marmoset technical work. In addition, we acknowledge the contribution of C. Hope Bias, Karla Block, Michelle Champagne, Julian Burt, Russell Olson, and Amy Dean at WRAIR for their involvement in the virus neutralization assay testing. Finally, we extend our appreciation to Dr. Nelson L. Michael for providing constructive input in this manuscript. This study was supported by the Peer Reviewed Medical Research Program (PRMRP; Award No. W81XWH-19-2-0020) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), and partially supported by the P51 grant (award number P51OD011133) awarded to SNPRC by National Institute of Health. The part of this study involving human serum IgG purification was supported in part by a cooperative agreement (W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense. Competing interests: S.J.T. is the lead inventor on the ZPIV patent filed by the US Army and assigned all rights to the US Government. K.M. has received funding from the U.S. Defense Health Agency and the National Institutes of Health during the execution of the research described in this manuscript. K.M. is currently an employee of Pfizer, Inc. M.A.B., I.-J.K., J.L.P., C.N.R., and other authors have no competing interests."